罕见自身免疫性风湿病患者接种SARS-CoV-2疫苗后的体液与细胞免疫
这项观察性研究比较了50例罕见自身免疫性风湿病(RAIRD)患者与健康对照在第二剂SARS-CoV-2疫苗接种后的抗体与T细胞反应。RAIRD患者抗刺突抗体中位水平显著低于健康对照(P<0.0001),部分患者抗体不可测或低于对照最低值;无/低抗体组记忆T细胞数量减少且功能受损。
要点
- RAIRD患者第二剂疫苗接种后抗刺突抗体中位水平显著低于健康对照(P<0.0001)。
- 15例(33%)患者抗体不可测,26例(57%)低于健康对照最低水平。
- 无/低抗体组记忆T细胞数量减少且缺乏增殖与功能能力。
核心结论
- 接种两剂疫苗后,多数RAIRD患者抗体水平低于健康对照最低值,且抗刺突T细胞较低。
- 无/低抗体RAIRD患者的记忆T细胞数量减少、质量差,缺乏增殖和功能能力。
研究设计与样本
- 观察性研究,纳入50例RAIRD患者(31例AAV、4例其他系统性血管炎、9例SLE、6例肌炎),比较第二剂SARS-CoV-2疫苗接种后体液与细胞介导T细胞反应与健康对照的差异。
主要发现
- RAIRD患者抗刺突抗体中位水平显著低于健康对照(P<0.0001)。
- 15例(33%)患者抗体水平不可测,26例(57%)低于健康对照最低水平。
- 与较长疫苗接种前间隔相比,最近12个月内使用利妥昔单抗与免疫原性降低相关(P=0.003)。
- 无/低抗体组与高抗体组之间B细胞百分比(P=0.03)和刺突特异性CD4+ T细胞(P=0.02)存在显著差异。
- 无/低抗体组终末分化(耗竭)T细胞百分比较高。
关键数值与推荐
- RAIRD患者抗刺突抗体中位水平显著低于健康对照(P<0.0001)。
- 15例(33%)患者抗体不可测,26例(57%)低于健康对照最低水平。
- 最近12个月内使用利妥昔单抗与免疫原性降低相关(P=0.003)。
- 无/低抗体组与高抗体组B细胞百分比差异P=0.03,刺突特异性CD4+ T细胞差异P=0.02。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Coronavirus 2019 vaccine responses in rare autoimmune rheumatic diseases (RAIRDs) remain poorly understood; in particular there is little known about whether people develop effective T cell responses. We conducted an observational study to evaluate the short-term humoral and cell-mediated T cell response after the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in RAIRD patients compared with healthy controls (HCs). METHODS: Blood samples were collected after the second dose and anti-spike, anti-nucleocapsid antibody levels and SARS-CoV-2-specific T cell responses were measured and compared with those of HCs. Activation-induced marker and deep phenotyping assays were used to identify differences in T cells between high and no/low antibody groups, followed by multidimensional clustering. RESULTS: A total of 50 patients with RAIRDs were included (31 with AAV, 4 with other systemic vasculitis, 9 with SLE and 6 with myositis). The median anti-spike levels were significantly lower in RAIRD patients compared with HCs (P < 0.0001). Fifteen (33%) patients had undetectable levels and 26 (57%) had levels lower than the lowest HC. Rituximab in the last 12 months (P = 0.003) was associated with reduced immunogenicity compared with a longer pre-vaccination period. There was a significant difference in B cell percentages (P = 0.03) and spike-specific CD4+ T cells (P = 0.02) between no/low antibody vs high antibody groups. Patients in the no/low antibody group had a higher percentage of terminally differentiated (exhausted) T cells. CONCLUSIONS: Following two doses, most RAIRD patients have lower antibody levels than the lowest HC and lower anti-spike T cells. RAIRD patients with no/low antibodies have diminished numbers and poor quality of memory T cells that lack proliferative and functional capacities.
引用
- Gumber L, Gomez N, Hopkins G, et al. Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination. Rheumatology (Oxford). 2023. PMID: 36250898. doi:10.1093/rheumatology/keac574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。